Stock NTRA NATERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Natera, Inc.

Equities

NTRA

US6323071042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
93.72 USD -0.46% Intraday chart for Natera, Inc. +2.67% +49.62%
May. 01 Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage CI
Apr. 18 Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Natera to Report its First Quarter 2024 Results on May 9
BU
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
BU
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
BU
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
BU
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients
AQ
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
BU
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AQ
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
BU
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
AQ
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
BU
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
BU
Natera, Inc. - New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
AQ
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
BU
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
AQ
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
BU
Natera Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan
AQ
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
BU
Natera to Participate in March Investor Conferences
BU
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Medicare Extends Coverage of Natera's Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
  5. Press Releases